The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receiv...
"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representa...
Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifo...
BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial ...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
Safety data encouraging with no graft-versus-host-disease and no neurotoxicity Updated data highlighted in podium presentation at the 17th International...
Transcenta in-licensed the Great China rights of Blosozumab from Eli Lilly and Company ("Eli Lilly") for development and commercialization in Greater China...
ASC40 is an oral, selective small molecule inhibitor of FASN. Mechanisms of ASC40 for acne are (1) direct inhibition of facial sebum production, through in...
"Today's approval is an important advance in cell therapy treatment in patients with blood cancers," said Peter Marks, M.D., Ph.D., director of the FDA's C...
A preclinical study using stem cells to produce progenitor photoreceptor cells—light-detecting cells found in the eye—and then transplant...
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medic...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative pre...
© 2025 Biopharma Boardroom. All Rights Reserved.
